Novel Insights into Osteoarthritis Joint Pathology from Studies in Mice

Current Rheumatology Reports

Volumn 17, Issue 8, 2015, Pages

  Moon, Paxton M ^a   Beier, Frank ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CHILDREN S HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Bone; Cartilage; DMM; Joint; KO; Mouse; Osteoarthritis; Synovium

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; BONE MORPHOGENETIC PROTEIN 2; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; COLLAGEN TYPE 2; COLLAGENASE 3; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STROMELYSIN; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ADAMTS5 GENE; AUTOPHAGY; BONE REMODELING; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE HOMEOSTASIS; CELL SURVIVAL; DIO2 GENE; DISEASE ASSOCIATION; DISEASE MODEL; EXTRACELLULAR MATRIX; GENE; GENE DELETION; GENE EXPRESSION; HOMEOSTASIS; HSPG2 GENE; JOINT PATHOLOGY; MIG 6 GENE; MMP3 GENE; MOLECULAR PATHOLOGY; MOUSE; MOUSE STRAIN; MUTATIONAL ANALYSIS; NONHUMAN; OSTEOARTHRITIS; OSTEOPHYTE; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SYNOVIUM; ANIMAL; ARTICULAR CARTILAGE; EXPERIMENTAL ARTHRITIS; PHYSIOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOPHAGY; BONE REMODELING; CARTILAGE, ARTICULAR; HOMEOSTASIS; MICE; OSTEOARTHRITIS; OSTEOPHYTE; PROTEOLYSIS; SYNOVIAL MEMBRANE;

EID: 84932640293     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0524-1     Document Type: Review

References (91)

1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30. doi:10.1136/annrheumdis-2013-204763.
2. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437–41. doi:10.1038/nrrheum.2014.44.
3. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115–26. doi:10.1016/s0140-6736(11)60243-2.
4. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35. doi:10.1002/art.23176.
5. Chu CR, Williams AA, Coyle CH, Bowers ME. Early diagnosis to enable early treatment of pre-osteoarthritis. Arthritis Res Ther. 2012;14(3):212. doi:10.1186/ar3845.
6. Fang H, Beier F. Mouse models of osteoarthritis: modelling risk factors and assessing outcomes. Nat Rev Rheumatol. 2014;10(7):413–21. doi:10.1038/nrrheum.2014.46.
7. Aigner T, Sachse A, Gebhard PM, Roach HI. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev. 2006;58(2):128–49. doi:10.1016/j.addr.2006.01.020.
8. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001;3(2):107–13.
9. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005;434(7033):648–52. doi:10.1038/nature03417.
10. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002;277(25):22201–8. doi:10.1074/jbc.M200431200.
11. Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta. 2012;1824(1):133–45. doi:10.1016/j.bbapap.2011.06.020.
12. Wang M, Sampson ER, Jin H, Li J, Ke QH, Im HJ, et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013;15(1):R5. doi:10.1186/ar4133.
13. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Investig. 1997;99(7):1534–45.
14. Caterson B, Flannery CR, Hughes CE, Little CB. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000;19(4):333–44. doi:10.1016/S0945-053X(00)00078-0.
15. Fosang AJ, Little CB. Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheumatol. 2008;4(8):420–7.
16. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008;10(3):R63. doi:10.1186/ar2434.
17. Little CB, Fosang AJ. Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis—insights from studies of aggrecan and collagen proteolysis? Curr Drug Targets. 2010;11(5):561–75.
18. Li NG, Shi ZH, Tang YP, Wang ZJ, Song SL, Qian LH, et al. New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem. 2011;18(7):977–1001.
19. Schipani E. Hypoxia and HIF-1α in chondrogenesis. Semin Cell Dev Biol. 2005;16(4–5):539–46. doi:10.1016/j.semcdb.2005.03.003.
20. Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS. Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum. 2011;63(9):2732–43. doi:10.1002/art.30451.
21. Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med. 2010;16(6):687–93. doi:10.1038/nm.2153.
22. Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, et al. Transcriptional regulation of endochondral ossification by HIF-2[alpha] during skeletal growth and osteoarthritis development. Nat Med. 2010;16(6):678–86. http://www.nature.com/nm/journal/v16/n6/suppinfo/nm.2146_S1.html.
23. Caramés B, Taniguchi N, Otsuki S, Blanco FJ, Lotz M. Autophagy is a protective mechanism in normal cartilage and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum. 2010;62(3):791–801. doi:10.1002/art.27305.
24. Mizushima N. Physiological functions of autophagy. Curr Top Microbiol Immunol. 2009;335:71–84. doi:10.1007/978-3-642-00302-8_3.
25. Zhang Y, Vasheghani F, Li YH, Blati M, Simeone K, Fahmi H, et al. Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204599.
26. Carames B, Hasegawa A, Taniguchi N, Miyaki S, Blanco FJ, Lotz M. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis. 2012;71(4):575–81. doi:10.1136/annrheumdis-2011-200557.
27. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20(7):1981–91. doi:10.1091/mbc.E08-12-1248.
28. Weng T, Xie Y, Yi L, Huang J, Luo F, Du X, et al. Loss of Vhl in cartilage accelerated the progression of age-associated and surgically induced murine osteoarthritis. Osteoarthr Cartil. 2014;22(8):1197–205. doi:10.1016/j.joca.2014.06.031.
29. Huang MJ, Wang L, Jin DD, Zhang ZM, Chen TY, Jia CH, et al. Enhancement of the synthesis of n-3 PUFAs in fat-1 transgenic mice inhibits mTORC1 signalling and delays surgically induced osteoarthritis in comparison with wild-type mice. Ann Rheum Dis. 2014;73(9):1719–27. doi:10.1136/annrheumdis-2013-203231.
30. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell. 1993;77(1):67–76.
31. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, et al. 15-Hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist. Mol Pharmacol. 2010;77(2):171–84. doi:10.1124/mol.109.060541.
32. Kapadia R, Yi J-H, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13:1813–26.
33. Monemdjou R, Vasheghani F, Fahmi H, Perez G, Blati M, Taniguchi N, et al. Association of cartilage-specific deletion of peroxisome proliferator-activated receptor gamma with abnormal endochondral ossification and impaired cartilage growth and development in a murine model. Arthritis Rheum. 2012;64(5):1551–61. doi:10.1002/art.33490.
34. Vasheghani F, Monemdjou R, Fahmi H, Zhang Y, Perez G, Blati M, et al. Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype. Am J Pathol. 2013;182(4):1099–106. doi:10.1016/j.ajpath.2012.12.012.
35. Vasheghani F, Zhang Y, Li YH, Blati M, Fahmi H, Lussier B, et al. PPARgamma deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Ann Rheum Dis. 2015;74(3):569–78. doi:10.1136/annrheumdis-2014-205743. In this very recent study by Vasheghani et al. a critical link between metabolic dysregulation and disrupted autophagy mediated by enhanced mTOR signalling is proposed. As we attempt to put together a more complete picture of joint pathology in OA, studies linking critical mediators of various important homeostatic and catabolic process are of tremendous value.
36. Ratneswaran A, LeBlanc EA, Walser E, Welch I, Mort JS, Borradaile N, et al. Peroxisome proliferator-activated receptor delta promotes the progression of posttraumatic osteoarthritis in a mouse model. Arthritis Rheumatol (Hoboken, NJ). 2015;67(2):454–64. doi:10.1002/art.38915.
37. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85(1):37–45.
38. de Munter W, Blom AB, Helsen MM, Walgreen B, van der Kraan PM, Joosten LA, et al. Cholesterol accumulation caused by low density lipoprotein receptor deficiency or a cholesterol-rich diet results in ectopic bone formation during experimental osteoarthritis. Arthritis Res Ther. 2013;15(6):R178. doi:10.1186/ar4367.
39. Triantaphyllidou IE, Kalyvioti E, Karavia E, Lilis I, Kypreos KE, Papachristou DJ. Perturbations in the HDL metabolic pathway predispose to the development of osteoarthritis in mice following long-term exposure to western-type diet. Osteoarthr Cartil. 2013;21(2):322–30. doi:10.1016/j.joca.2012.11.003.
40. Gierman LM, Kuhnast S, Koudijs A, Pieterman EJ, Kloppenburg M, van Osch GJ, et al. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice—a translational model for atherosclerosis. Ann Rheum Dis. 2014;73(5):921–7. doi:10.1136/annrheumdis-2013-203248.
41. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–87.
42. Bush JR, Berube NG, Beier F. A new prescription for growth? Statins, cholesterol and cartilage homeostasis. Osteoarthr Cartil. 2015;23(4):503–6. doi:10.1016/j.joca.2015.01.002.
43. Goldring MB, Otero M, Plumb DA, Dragomir C, Favero M, El Hachem K, et al. Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis. Eur Cells Mater. 2011;21:202–20.
44. Gierman LM, van der Ham F, Koudijs A, Wielinga PY, Kleemann R, Kooistra T, et al. Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice. Arthritis Rheum. 2012;64(4):1172–81. doi:10.1002/art.33443.
45. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42(1–3):23–30. doi:10.1016/S0162-3109(99)00007-7.
46. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, et al. Identification of a central role for complement in osteoarthritis. Nat Med. 2011;17(12):1674–9. doi:10.1038/nm.2543.
47. Takebe K, Rai MF, Schmidt EJ, Sandell LJ. The chemokine receptor CCR5 plays a role in post-traumatic cartilage loss in mice, but does not affect synovium and bone. Osteoarthr Cartil. 2015;23(3):454–61. doi:10.1016/j.joca.2014.12.002.
48. Thomas N, Li P, Fleming BC, Chen Q, Wei X, Pan X, et al. Attenuation of cartilage pathogenesis in post-traumatic osteoarthritis (PTOA) in mice by blocking the stromal derived factor 1 receptor (CXCR4) with the specific inhibitor, AMD3100. J Orthop Res. 2015. doi:10.1002/jor.22862.
49. Sherwood J, Bertrand J, Nalesso G, Poulet B, Pitsillides A, Brandolini L, et al. A homeostatic function of CXCR2 signalling in articular cartilage. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-205546. This novel paper by Sherwood et al. presents exciting new insights into the homeostatic regulation of articular cartilage by an unlikely factor, CXCR2. This is of importance to the field because generally chemokine signaling is viewed as catabolic, but in this case the opposite appears to be true.
50. Kozhemyakina E, Lassar AB, Zelzer E. A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation. Development (Cambridge, England). 2015;142(5):817–31. doi:10.1242/dev.105536.
51. Pitsillides AA, Beier F. Cartilage biology in osteoarthritis—lessons from developmental biology. Nat Rev Rheumatol. 2011;7(11):654–63. doi:10.1038/nrrheum.2011.129.
52. Sun MM-G, Beier F. Chondrocyte hypertrophy in skeletal development, growth, and disease. Birth Defects Res C Embryo Today Rev. 2014;102(1):74–82. doi:10.1002/bdrc.21062.
53. Luyten FP, Tylzanowski P, Lories RJ. Wnt signaling and osteoarthritis. Bone. 2009;44(4):522–7. doi:10.1016/j.bone.2008.12.006.
54. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Min Res Off J Am Soc Bone Miner Res. 2009;24(1):12–21. doi:10.1359/jbmr.080901.
55. Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M. Wnt/beta-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Investig. 2008;88(3):264–74. doi:10.1038/labinvest.3700747.
56. Litherland GJ, Hui W, Elias MS, Wilkinson DJ, Watson S, Huesa C, et al. Glycogen synthase kinase 3 inhibition stimulates human cartilage destruction and exacerbates murine osteoarthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66(8):2175–87. doi:10.1002/art.38681.
57. Funck-Brentano T, Bouaziz W, Marty C, Geoffroy V, Hay E, Cohen-Solal M. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol (Hoboken, NJ). 2014;66(11):3028–39. doi:10.1002/art.38799.
58. Oh H, Chun CH, Chun JS. Dkk-1 expression in chondrocytes inhibits experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum. 2012;64(8):2568–78. doi:10.1002/art.34481.
59. Zhu M, Chen M, Zuscik M, Wu Q, Wang Y-J, Rosier RN, et al. Inhibition of β-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 2008;58(7):2053–64. doi:10.1002/art.23614.
60. Tamamura Y, Otani T, Kanatani N, Koyama E, Kitagaki J, Komori T, et al. Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem. 2005;280(19):19185–95. doi:10.1074/jbc.M414275200.
61. Chen CG, Thuillier D, Chin EN, Alliston T. Chondrocyte-intrinsic Smad3 represses Runx2-inducible matrix metalloproteinase 13 expression to maintain articular cartilage and prevent osteoarthritis. Arthritis Rheum. 2012;64(10):3278–89. doi:10.1002/art.34566.
62. Davidson ENB, Van der Kraan PM, van Den Berg WB. TGF-β and osteoarthritis. Osteoarthr Cartil. 2007;15(6):597–604.
63. Meulenbelt I, Bos SD, Chapman K, van der Breggen R, Houwing-Duistermaat JJ, Kremer D, et al. Meta-analyses of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Ann Rheum Dis. 2011;70(1):164–7.
64. Bomer N, Cornelis FM, Ramos YF, den Hollander W, Storms L, van der Breggen R, et al. The effect of forced exercise on knee joints in Dio2−/− mice: type II iodothyronine deiodinase-deficient mice are less prone to develop OA-like cartilage damage upon excessive mechanical stress. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-206608. Our highlighting of this study by Bomer et al. is based on 2 factors. Firstly, this study identifies Dio2, a gene linked to increased OA susceptibility in humans, as a novel mediator of joint pathology in OA in mice. Secondly, it presents an exciting new mouse model of OA induction for the community that ultimately provides a more physiological model of disease induction and progression.
65. Waung JA, Bassett JH, Williams GR. Adult mice lacking the type 2 iodothyronine deiodinase have increased subchondral bone but normal articular cartilage. Thyroid Off J Am Thyroid Assoc. 2015;25(3):269–77. doi:10.1089/thy.2014.0476.
66. Zhang X, Zhu J, Li Y, Lin T, Siclari VA, Chandra A, et al. Epidermal growth factor receptor (EGFR) signaling regulates epiphyseal cartilage development through β-catenin-dependent and -independent pathways. J Biol Chem. 2013;288(45):32229–40.
67. Zhang X, Siclari VA, Lan S, Zhu J, Koyama E, Dupuis HL, et al. The critical role of the epidermal growth factor receptor in endochondral ossification. J Bone Miner Res. 2011;26(11):2622–33. doi:10.1002/jbmr.502.
68. Appleton CTG, Usmani SE, Bernier SM, Aigner T, Beier F. Transforming growth factor α suppression of articular chondrocyte phenotype and Sox9 expression in a rat model of osteoarthritis. Arthritis Rheum. 2007;56(11):3693–705. doi:10.1002/art.22968.
69. Appleton CTG, Usmani SE, Mort JS, Beier F. Rho/ROCK and MEK/ERK activation by transforming growth factor-[alpha] induces articular cartilage degradation. Lab Investig. 2009;90(1):20–30.
70. Zhang Y-W, Su Y, Lanning N, Swiatek PJ, Bronson RT, Sigler R, et al. Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A. 2005;102(33):11740–5.
71. Staal B, Williams BO, Beier F, Vande Woude GF, Zhang YW. Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proc Natl Acad Sci U S A. 2014;111(7):2590–5. doi:10.1073/pnas.1400744111.
72. Pest MA, Russell BA, Zhang YW, Jeong JW, Beier F. Disturbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction. Arthritis Rheumatol (Hoboken, NJ). 2014;66(10):2816–27. doi:10.1002/art.38758.
73. Shepard JB, Jeong JW, Maihle NJ, O’Brien S, Dealy CN. Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo. Arthritis Res Ther. 2013;15(3):R60. doi:10.1186/ar4233.
74. Joiner DM, Less KD, Van Wieren EM, Zhang YW, Hess D, Williams BO. Accelerated and increased joint damage in young mice with global inactivation of mitogen-inducible gene 6 after ligament and meniscus injury. Arthritis Res Ther. 2014;16(2):R81. doi:10.1186/ar4522.
75. Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol. 2011;7(1):43–9. doi:10.1038/nrrheum.2010.197.
76. Roman-Blas JA, Herrero-Beaumont G. Targeting subchondral bone in osteoporotic osteoarthritis. Arthritis Res Ther. 2014;16(6):494. doi:10.1186/s13075-014-0494-0.
77. Funck-Brentano T, Lin H, Hay E, Ah Kioon MD, Schiltz C, Hannouche D, et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One. 2012;7(3), e33543. doi:10.1371/journal.pone.0033543.
78. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhibition of TGF-[beta] signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704–12. doi:10.1038/nm.3143. http://www.nature.com/nm/journal/v19/n6/abs/nm.3143.html-supplementary-information.
79. Bush JR, Beier F. TGF-[beta] and osteoarthritis—the good and the bad. Nat Med. 2013;19(6):667–9. doi:10.1038/nm.3228.
80. Jackson MT, Moradi B, Zaki S, Smith MM, McCracken S, Smith SM, et al. Depletion of protease-activated receptor 2 but not protease-activated receptor 1 may confer protection against osteoarthritis in mice through extracartilaginous mechanisms. Arthritis Rheumatol (Hoboken, NJ). 2014;66(12):3337–48. doi:10.1002/art.38876.
81. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthr Cartil. 2007;15(3):237–44. doi:10.1016/j.joca.2006.11.006.
82. Menkes CJ, Lane NE. Are osteophytes good or bad? Osteoarthr Cartil. 2004;12(Suppl A):S53–4.
83. Kaneko H, Ishijima M, Futami I, Tomikawa-Ichikawa N, Kosaki K, Sadatsuki R, et al. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol. 2013;32(3–4):178–87. doi:10.1016/j.matbio.2013.01.004.
84. Davidson EN, Vitters EL, Bennink MB, van Lent PL, van Caam AP, Blom AB, et al. Inducible chondrocyte-specific overexpression of BMP2 in young mice results in severe aggravation of osteophyte formation in experimental OA without altering cartilage damage. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204528.
85. Chen L, Li DQ, Zhong J, Wu XL, Chen Q, Peng H, et al. IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis. Osteoarthr Cartil. 2011;19(6):711–8. doi:10.1016/j.joca.2011.01.018.
86. Zanotti S, Canalis E. Interleukin 6 mediates selected effects of Notch in chondrocytes. Osteoarthr Cartil. 2013;21(11):1766–73. doi:10.1016/j.joca.2013.08.010.
87. Fosang AJ, Lees S, Golub SB, Last K, Zeng W, Jackson DC, et al. Bioactivity in an aggrecan 32mer fragment is mediated via Toll-like receptor 2. Arthritis Rheumatol. 2015. doi:10.1002/art.39063.
88. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8(6):R187. doi:10.1186/ar2099.
89. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012;109(50):20602–7. doi:10.1073/pnas.1209294110.
90. Cuellar JM, Scuderi GJ, Cuellar VG, Golish SR, Yeomans DC. Diagnostic utility of cytokine biomarkers in the evaluation of acute knee pain. J Bone Joint Surg Am. 2009;91(10):2313–20. doi:10.2106/jbjs.h.00835.
91. Pest MA, Beier F. Developmental biology: is there such a thing as a cartilage-specific knockout mouse? Nat Rev Rheumatol. 2014;10(12):702–4. doi:10.1038/nrrheum.2014.168.